Terms: = Leukemia AND MYH11, ENSG00000133392, 4629 AND Treatment
106 results:
1. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract] [Full Text] [Related]
2. Therapy-related acute myeloid leukemia with
Yang X; Liu Q; Zhang R; Yang X; Wang L; Zhang Z; Li Y; Lin L
Indian J Pathol Microbiol; 2023; 66(4):865-867. PubMed ID: 38084551
[TBL] [Abstract] [Full Text] [Related]
3. CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Shen YJ; Zhang Y; Chang J; Wang HF; Ye XN; Zhu L; Jin J; Zhu HH
Ann Hematol; 2023 Jul; 102(7):1731-1738. PubMed ID: 37145324
[TBL] [Abstract] [Full Text] [Related]
4. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
[TBL] [Abstract] [Full Text] [Related]
5. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study.
Scott S; Dillon R; Thiede C; Sadiq S; Cartwright A; Clouston HJ; Travis D; Mokretar K; Potter N; Chantry A; Whitby L
Blood Adv; 2023 Jul; 7(14):3686-3694. PubMed ID: 36939402
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive molecular understanding of pediatric acute myeloid leukemia.
Shiba N
Int J Hematol; 2023 Feb; 117(2):173-181. PubMed ID: 36653696
[TBL] [Abstract] [Full Text] [Related]
7. Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases.
Chen Y; Wang Q; Cen J; Xu C; Tao TT; Xie J; Shen W; Gong Y; Pan J; Yao L
Mol Carcinog; 2023 Feb; 62(2):117-121. PubMed ID: 36321418
[TBL] [Abstract] [Full Text] [Related]
8. Explainable artificial intelligence for precision medicine in acute myeloid leukemia.
Gimeno M; San José-Enériz E; Villar S; Agirre X; Prosper F; Rubio A; Carazo F
Front Immunol; 2022; 13():977358. PubMed ID: 36248800
[TBL] [Abstract] [Full Text] [Related]
9. [Myeloid sarcomas of the shoulder and testis relapsing 9 years after allogenic stem cell transplantation for acute myeloid leukemia].
Yamamoto R; Suyama T; Yoshizawa Y; Shimizu M; Kuroda A; Shinagawa A
Rinsho Ketsueki; 2022; 63(8):860-864. PubMed ID: 36058855
[TBL] [Abstract] [Full Text] [Related]
10. Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia.
Karlsson L; Nyvold CG; Soboli A; Johansson P; Palmqvist L; Tierens A; Hasle H; Lausen B; Jónsson ÓG; Jürgensen GW; Ebbesen LH; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2022 Dec; 44(6):1094-1101. PubMed ID: 35918824
[TBL] [Abstract] [Full Text] [Related]
11. Acute hepatitis-like presentation with cholestasis of CBFB-myh11-positive acute myeloid leukemia in an adult male: a case report.
Spinelli I; De Santis A; Cesini L; Riminucci M; Corsi A; Forlino M; Perrone EP; Minotti C; Cartoni C
J Med Case Rep; 2022 Jul; 16(1):294. PubMed ID: 35907896
[TBL] [Abstract] [Full Text] [Related]
12. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical Characteristics and Prognosis of Acute Myeloid leukemia Patients with inv(16)/t(16;16)(p13.1;q22) and/or CBFβ-myh11].
Wang YM; Cai P; Zhou MJ; Gong YY; Pan JL; Cen JN; Yang XF; Chen SN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):. PubMed ID: 35400360
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical Characteristics and Prognosis of Acute Myeloid leukemia Patients with inv(16)/t(16;16)(p13.1;q22) and/or CBFβ-myh11].
Wang YM; Cai P; Zhou MJ; Gong YY; Pan JL; Cen JN; Yang XF; Chen SN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):367-372. PubMed ID: 35395965
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic of Core Binding Factor (CBF) Acute Myeloid leukemia With Complex Karyotype.
Marcault C; Boissel N; Haferlach C; Loschi M; Raynaud S; Cluzeau T
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e199-e205. PubMed ID: 34674982
[TBL] [Abstract] [Full Text] [Related]
16. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract] [Full Text] [Related]
17. All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
Dembitz V; Lalic H; Tomic B; Smoljo T; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
Int J Hematol; 2022 Jan; 115(1):43-53. PubMed ID: 34546543
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
Konuma T; Kondo T; Masuko M; Shimizu H; Shiratori S; Fukuda T; Kato J; Sawa M; Ozawa Y; Ota S; Uchida N; Kanda Y; Kako S; Fujisawa S; Fukushima K; Ichinohe T; Atsuta Y; Yanada M;
Bone Marrow Transplant; 2021 Nov; 56(11):2779-2787. PubMed ID: 34272486
[TBL] [Abstract] [Full Text] [Related]
19. Incidental identification of inv(16)(p13.1q22)/
Quesada AE; Luthra R; Jabbour E; Patel KP; Khoury JD; Tang Z; Alvarez H; Mallampati S; Garcia-Manero G; Montalban-Bravo G; Medeiros LJ; Kanagal-Shamanna R
Cold Spring Harb Mol Case Stud; 2021 Jun; 7(3):. PubMed ID: 34117074
[TBL] [Abstract] [Full Text] [Related]
20. Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
Owen N; Minko IG; Moellmer SA; Cammann SK; Lloyd RS; McCullough AK
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836581
[TBL] [Abstract] [Full Text] [Related]
[Next]
